Panakeia PANProfiler Breast receives CE mark

Nov 16, 2021
1 min read

A new AI-based test that can predict the most effective treatment from images of routine cancer samples has been approved for use in the UK and EU, speeding up diagnosis and reducing the need for lab testing. Read more

Panakeia to attend and present at upcoming scientific and business conferences

Cambridge, UK, 9 April 2025 – Panakeia (“the Company”), a pioneer in AI-enabled multi-omic biomarker profiling, is pleased to confirm...

Panakeia to present results of blinded multi-site validation of its AI-driven molecular profiling tool for colon cancer, PANProfiler Colon, at ASCO GI Symposium

Panakeia launches PANProfiler Colon, an AI-driven tool for precision medicine in colon cancer

PANProfiler Colon determines MSI/dMMR status in minutes from colon cancer tissue samples Entirely digital, AI-driven molecular profiling...

Comments